Back to Journals » Cancer Management and Research » Volume 11

Asunercept as an innovative therapeutic approach for recurrent glioblastoma and other malignancies

Authors Krendyukov A, Gieffers C

Received 25 May 2019

Accepted for publication 25 July 2019

Published 2 September 2019 Volume 2019:11 Pages 8095—8100

DOI https://doi.org/10.2147/CMAR.S216675

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Amy Norman

Peer reviewer comments 2

Editor who approved publication: Dr Eileen O'Reilly


Andriy Krendyukov, Christian Gieffers

Apogenix AG, Heidelberg, Germany

Correspondence: Andriy Krendyukov
Apogenix AG, Im Neuenheimer Feld 584, Heidelberg 69120, Germany
Email andriy.krendyukov@apogenix.com

Abstract: Glioblastoma is the most common and aggressive malignant tumor of the central nervous system. Despite the existing high unmet medical needs, the past few decades have seen no notable improvement in overall survival for glioblastoma patients. One active area of research to develop new therapeutic options for this disease is focusing on the CD95/Fas receptor and its ligand CD95L/FasL. It is now recognized that in addition to its role in programmed cell death, CD95/CD95L signaling is involved in a wide range of other apoptotic and non-apoptotic pathways directed toward T-effector cells and cells in the tumor microenvironment involved in tumor progression and invasiveness. Asunercept is a first-in-class recombinant glycosylated fusion protein, which has been designed to selectively bind to CD95L and therefore disrupt CD95/CD95L signaling. The current report provides a brief overview of the role of the CD95/CD95L signaling pathway in cancer pathogenesis and discusses how asunercept was designed to bind and neutralize CD95L and disrupt signaling thereby potentially improving outcomes in glioblastoma and other malignancies.

Keywords: CD95/CD95L, apoptosis, asunercept, APG101, glioblastoma, immuno-oncology

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]